Biocon Biologics Receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars Bengaluru, Karnataka, India, July 7, 2025  Biocon Biologics Ltd (BBL), a fully integrated global biosimilars ...

A 74-year-old man sustained a T12 compression fracture after being rear-ended by an unlicensed driver in Henrico County.

Indian biosimilars company Biocon Biologics, a subsidiary of Biocon Ltd (BSE: 532520), today announced that the UK’s ...

Biocon Biologics receives marketing authorizations for Vevzuo and Evfraxy biosimilars for bone-related diseases in the UK.

New Delhi: Biocon Ltd on Monday said its arm Biocon Biologics Ltd has received marketing authorisations from the Medicines ...

Biocon Biologics receives UK MHRA approval for Vevzuo & Evfraxy, biosimilars of Denosumab, to treat bone diseases in adults & ...

Biocon Biologics announced that the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisations in the United Kingdom (UK) for Vevzuo and Evfraxy, biosimilars of ...

Clinical studies have demonstrated that both biosimilars are comparable in safety and efficacy to the reference product, the ...

Biocon said that Biocon Biologics has received marketing authorisations from UK Medicines and Healthcare products Regulatory Agency for Vevzuo and Evfraxy, biosimilars of Denosumab.

Fractures of the cervical spine are a medical emergency and may lead to permanent paralysis and even death. Accurate diagnosis in patients with suspected fractures by computed tomography (CT) is ...

Denosumab is a human monoclonal antibody that targets and binds a protein known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand).

CMS is adding prior authorization requirements for certain fee-for-service procedures under traditional Medicare as part of its new Wasteful and Inappropriate Service Reduction model. A total of 17 ...